Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
about
Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma modelAn update on vaccine therapy and other immunotherapeutic approaches for glioblastomaEvaluation of MHC class I peptide binding prediction servers: applications for vaccine researchAdeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy.Exploiting the critical perioperative period to improve long-term cancer outcomesCellular cancer vaccines: an update on the development of vaccines generated from cell surface antigens.Tumor-induced endothelial cell surface heterogeneity directly affects endothelial cell escape from a cell-mediated immune response in vitro.Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer.Enhancement of the Immunostimulatory Functions of Ex Vivo-Generated Dendritic Cells from Early-Stage Colon Cancer Patients by Consecutive Exposure to Low Doses of Sequential-Kinetic-Activated IL-4 and IL-12. A Preliminary Study.Lymphatic metastasis and nm23H1 genetic instability in Chinese colon cancer patients.A Platform for Designing Genome-Based Personalized Immunotherapy or Vaccine against Cancer.Adenoviral vector-based strategies for cancer therapy.Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system.Potential applications of nanoparticles in cancer immunotherapy.IL-10: Expanding the Immune Oncology Horizon.
P2860
Q24805875-7C985802-8DA7-4F57-8FBE-881A48D4DC2AQ27024830-D71C989D-4590-4470-9972-4C49791226EDQ33325636-51149319-D611-4BED-9D86-C32922DD5EE8Q33846007-75D4E480-32DC-4226-8612-CC3FA8A4109AQ33871661-B9C43F16-5220-4A53-9F62-909DF27C17D1Q34154644-DD324E70-7180-42D4-8398-2373E8D17AB0Q34329922-98E2134E-421B-4D50-A10D-87A8FB987850Q34751465-12C5A815-0CF8-44BC-88F0-FF77293B821DQ36038020-9EAD17E0-5FCA-49D0-BA16-053EF394CB97Q36065576-9F13046C-58B9-4E5B-BCA8-05C7BE6C5A7CQ36188919-044E44E8-D84B-435D-8B14-526F1BE0B0EBQ37409025-83C5EF61-50CB-4F73-95FF-7CF137814118Q37635491-6FD660D7-3688-4729-88F5-D9041A6C1922Q38031222-B4FDE08E-EC2B-473A-9CF6-67E9F1261C8FQ39015434-F7E638BE-4E13-4F73-8FDE-A385A25CF953Q40217856-8B6FB27A-5F81-4A1D-B568-C6BFA84388E6
P2860
Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Failure of cancer vaccines: th ...... his approach to immunotherapy.
@ast
Failure of cancer vaccines: th ...... his approach to immunotherapy.
@en
Failure of cancer vaccines: th ...... his approach to immunotherapy.
@nl
type
label
Failure of cancer vaccines: th ...... his approach to immunotherapy.
@ast
Failure of cancer vaccines: th ...... his approach to immunotherapy.
@en
Failure of cancer vaccines: th ...... his approach to immunotherapy.
@nl
prefLabel
Failure of cancer vaccines: th ...... his approach to immunotherapy.
@ast
Failure of cancer vaccines: th ...... his approach to immunotherapy.
@en
Failure of cancer vaccines: th ...... his approach to immunotherapy.
@nl
P2093
P1433
P1476
Failure of cancer vaccines: th ...... his approach to immunotherapy.
@en
P2093
P304
P407
P577
2000-07-01T00:00:00Z